Synonym
Chlorphenesin Carbamate; Maolate; Rinlaxer; Chlorphensin carbamate; Kolpicortin-sine; NSC 82943; NSC82943; NSC-82943; U 19646; U19646; U-19646; OC-201; OC 201; OC201;
IUPAC/Chemical Name
[3-(4-chlorophenoxy)-2-hydroxypropyl] carbamate
InChi Key
SKPLBLUECSEIFO-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H12ClNO4/c11-7-1-3-9(4-2-7)15-5-8(13)6-16-10(12)14/h1-4,8,13H,5-6H2,(H2,12,14)
SMILES Code
C1=CC(=CC=C1OCC(COC(=O)N)O)Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
245.66
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yu JY, Song HH, Kim BG, Park HJ, Choi KS, Kwon YE. Relative bioavailability of
generic and branded 250-mg and 500-mg oral chlorphenesin carbamate tablets in
healthy Korean volunteers: a single-dose, randomized-sequence, open-label,
two-period crossover trial. Clin Ther. 2009 Nov;31(11):2735-43. doi:
10.1016/j.clinthera.2009.11.036. PubMed PMID: 20110015.
2: Okuyama S, Aihara H. Antinociceptive effect of chlorphenesin carbamate in
adjuvant arthritic rats. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):147-60.
PubMed PMID: 3823606.
3: Nozu T, Suwa T, Setoyama K, Kurachi M, Tanaka I. [Influence of the
enterohepatic circulation on the metabolism of chlorphenesin carbamate (CPC). I.
Comparison between guinea pigs and bile duct-ligated rats (author's transl)].
Yakugaku Zasshi. 1977 Nov;97(11):1189-94. Japanese. PubMed PMID: 616817.
4: Watanabe S, Araki H, Kawasaki H, Ueki S. [Electroencephalographic effects of
chlorphenesin carbamate, a new central muscle relaxant, in rabbits (author's
transl)]. Nihon Yakurigaku Zasshi. 1977 May;73(4):479-96. Japanese. PubMed PMID:
908544.
5: Kaiser DG, Shaw SR. GLC determination of chlorphenesin carbamate in serum. J
Pharm Sci. 1974 Jul;63(7):1094-7. PubMed PMID: 4852199.
6: Fukuda H, Kudo Y, Ono H, Kokubo M. [Pharmacologial studies on a centrally
acting muscle relaxant, chlorphenesin carbamate, with special reference to the
effect on the motor system]. Nihon Yakurigaku Zasshi. 1974 May;70(3):341-58.
Japanese. PubMed PMID: 4280376.
7: Lamphier TA. A comparison between propoxyphene hydrochloride (Darvon) and
chlorphenesin carbamate (Maolate) in musculoskeletal disorders. A controlled
study in 92 patients. Curr Ther Res Clin Exp. 1969 May;11(5):234-41. PubMed PMID:
4977392.
8: Bloomfield SS, Gaffney TE, Howett M. Comparative analgesic efficacy of
chlorphenesin carbamate and acetylsalicylic acid after episiotomy. Anesth Analg.
1967 Sep-Oct;46(5):515-20. PubMed PMID: 4861208.
9: Callahan JJ. Maolate (chlorphenesin carbamate) a new myanalgic drug in
industrial medicine. IMJ Ill Med J. 1967 Sep;132(3):304-5. PubMed PMID: 4383777.
10: Chlorphenesin carbamate (Maolate). Med Lett Drugs Ther. 1967 Aug
25;9(17):65-6. PubMed PMID: 6050659.
11: Karns RM, Winer JH. Chlorphenesin carbamate in the treatment of muscle spasm
and musculoskeletal disorders. Pac Med Surg. 1967 May-Jun;75(3):199-200. PubMed
PMID: 5232821.
12: Turner R, Rockwood CA. Chlorphenesin carbamate (maolate) in the relief of
muscle pain. Mil Med. 1967 May;132(5):371-4. PubMed PMID: 4962932.
13: Chesrow EJ, Kaplitz SE, Bernstein M, Breme JT, Marquardt GH. Clinical
evaluation of chlorphenesin carbamate (maolate) in spasticity, rigidity and pain
associated with neurologic and arthritic diseases. J Am Geriatr Soc. 1966
Sep;14(9):925-9. PubMed PMID: 5331689.
14: BUHLER DR. CHARACTERIZATION OF THE GLUCURONIDE CONJUGATE OF CHLORPHENESIN
CARBAMATE FROM THE RAT AND FROM MAN. Biochem Pharmacol. 1965 Mar;14:371-3. PubMed
PMID: 14314338.
15: STERN FH. CLINICAL TRIAL OF CHLORPHENESIN CARBAMATE IN PATIENTS WITH MUSCLE
SPASM. Clin Med (Northfield). 1963 Aug;70:1451-4. PubMed PMID: 15446076.
16: KOLODNY AL. Controlled clinical evaluation of a new muscle
relaxant--chlorphenesin carbamate. Psychosomatics. 1963 May-Jun;4:161-4. PubMed
PMID: 14034417.
17: Hara M, Hayashi H, Yoshida T, Murayama H. Studies on the kinetics and
mechanism of drug degradation. I. Kinetics and mechanism of degradation of
chlorphenesin carbamate in strongly alkaline aqueous solutions. Chem Pharm Bull
(Tokyo). 1986 Apr;34(4):1764-9. PubMed PMID: 3719877.
18: Kurachi M, Aihara H. Effect of a muscle relaxant, chlorphenesin carbamate, on
the spinal neurons of rats. Jpn J Pharmacol. 1984 Sep;36(1):7-13. PubMed PMID:
6503049.
19: Coskey RJ. Fixed drug eruption from chlorphenesin carbamate. JAMA. 1982 Jul
2;248(1):30-1. PubMed PMID: 6211558.
20: Aihara H, Kurachi M, Nakane S, Sasajima M, Ohzeki M. The action of
chlorphenesin carbamate on the frog spinal cord. Jpn J Pharmacol. 1980
Feb;30(1):29-36. PubMed PMID: 6967526.
